tirzepatide week 4 weight loss percentage The percent change in body from baseline to endpoint (Week 72) How are people losing weight

The mechanism remains unknown, and until it is identified, targeted prevention strategies cannot be developed

Lach-Trifilieff, E

SURMOUNT-OSA Study 2 SURMOUNT-OSA study 2 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were on and planned to continue to use PAP therapy for 52 weeks

This precision-wellness approach may improve both efficacy and side-effect management, helping you reach an optimal therapeutic dose with confidence and minimal unnecessary trial-and-error

Considering taking weight loss medicine

No ZEPBOUND-treated patients in OSA studies developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors or against native GIP or native GLP-1